A cost-effectiveness analysis of adjuvant therapies for resected adenocarcinoma of the rectum.

被引：0
|
作者：
Lee, JH [1 ]
机构：
[1] UNIV PENN,SCH MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 39卷 / 02期
关键词：
D O I：
10.1016/S0360-3016(97)80759-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 235
页数：1
相关论文
共 50 条
  • [41] A COST-EFFECTIVENESS ANALYSIS (CEA) OF ADJUVANT NIVOLUMAB FOR PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN FRANCE
    Paul, C.
    Massettti, M.
    Cotte, F. E.
    Moreau, R.
    Kassahun, S.
    Singh, P.
    Kim, I
    Gaudin, A. F.
    Leleu, H.
    VALUE IN HEALTH, 2022, 25 (12) : S180 - S180
  • [42] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN CANADA
    Amadi, A.
    Toor, K.
    Keeney, E.
    Thom, H.
    Singh, P.
    Kim, I
    Mameri, E.
    VALUE IN HEALTH, 2022, 25 (01) : S40 - S40
  • [43] VALUE OF ADJUVANT ONCOLOGY THERAPIES: METHODOLOGICAL CHALLENGES OF MODELLING COST-EFFECTIVENESS OF AN ADJUVANT TREATMENT IN AN ERA OF HIGH-COST ONCOLOGY TREATMENTS
    Kovacs, V
    Kiss, Z.
    Tichy, E.
    Benedict, A.
    VALUE IN HEALTH, 2018, 21 : S4 - S4
  • [44] Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC)
    Shroff, R. T.
    Javle, M. M.
    Krishnan, S.
    Cantor, S. B.
    Lee, J. E.
    Fleming, J. B.
    Varadhachary, G. R.
    Abbruzzese, J. L.
    Wolff, R. A.
    Elting, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Cost-effectiveness of Taxane/platinum and doxorubicin/platinum combination therapies in adjuvant treatment of endometrial cancer
    Srinivasan, Swetha
    Nguyen, Joehl T.
    Roberts, Megan C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 308 - 308
  • [46] Assessing the cost-effectiveness of emerging therapies in the ICU
    Chalfin, DB
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 20 (03) : 263 - 270
  • [47] Cost-effectiveness of novel therapies for overactive bladder
    Mayr, Craig A.
    Shepherd, Jonathan P.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) : 527 - 535
  • [48] Cost-effectiveness analysis of antiviral therapies for chronic hepatitis B in Taiwan
    Chan, KA
    Pwu, RF
    VALUE IN HEALTH, 2003, 6 (03) : 263 - 263
  • [49] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for early breast cancer
    Wardley, Andrew M.
    Cameron, David A.
    Bell, Richard
    Erny, Samuel
    Cohen, Carole
    Geary, Una
    Walzer, Stefan
    Gyldmark, Marlene
    ANNALS OF ONCOLOGY, 2006, 17 : 95 - 96
  • [50] COST-EFFECTIVENESS ANALYSIS OF ADJUVANT ANASTROZOL IN POSTMENOPAUSAL WOMEN WITH BREAST CANCER
    Sasse, Andre Deeke
    Sasse, Emma Chen
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (05): : 535 - 540
12345